241 related articles for article (PubMed ID: 7512568)
1. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
[TBL] [Abstract][Full Text] [Related]
2. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1995 Jun; 270(23):13826-33. PubMed ID: 7775440
[TBL] [Abstract][Full Text] [Related]
3. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1997 Jul; 272(29):18007-14. PubMed ID: 9218428
[TBL] [Abstract][Full Text] [Related]
4. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.
Scandella D; Gilbert GE; Shima M; Nakai H; Eagleson C; Felch M; Prescott R; Rajalakshmi KJ; Hoyer LW; Saenko E
Blood; 1995 Sep; 86(5):1811-9. PubMed ID: 7544643
[TBL] [Abstract][Full Text] [Related]
5. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
[TBL] [Abstract][Full Text] [Related]
6. Fine epitope mapping of monoclonal antibodies to the NH2-terminal part of von Willebrand factor (vWF) by using recombinant and synthetic peptides: interest for the localization of the factor VIII binding domain.
Jorieux S; Gaucher C; Piétu G; Chérel G; Meyer D; Mazurier C
Br J Haematol; 1994 May; 87(1):113-8. PubMed ID: 7524613
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
[TBL] [Abstract][Full Text] [Related]
8. A synthetic factor VIII peptide of eight amino acid residues (1677-1684) contains the binding region of an anti-factor VIII antibody which inhibits the binding of factor VIII to von Willebrand factor.
Foster PA; Fulcher CA; Houghten RA; Zimmerman TS
Thromb Haemost; 1990 Jun; 63(3):403-6. PubMed ID: 2119526
[TBL] [Abstract][Full Text] [Related]
9. A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation.
Nogami K; Shima M; Nishiya K; Hosokawa K; Saenko EL; Sakurai Y; Shibata M; Suzuki H; Tanaka I; Yoshioka A
Blood; 2002 Jun; 99(11):3993-8. PubMed ID: 12010799
[TBL] [Abstract][Full Text] [Related]
10. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
Saenko EL; Shima M; Gilbert GE; Scandella D
J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
[TBL] [Abstract][Full Text] [Related]
11. Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.
Lin JC; Ettinger RA; Schuman JT; Zhang AH; Wamiq-Adhami M; Nguyen PC; Nakaya-Fletcher SM; Puranik K; Thompson AR; Pratt KP
PLoS One; 2015; 10(1):e0116577. PubMed ID: 25615825
[TBL] [Abstract][Full Text] [Related]
12. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.
Shima M; Nakai H; Scandella D; Tanaka I; Sawamoto Y; Kamisue S; Morichika S; Murakami T; Yoshioka A
Br J Haematol; 1995 Nov; 91(3):714-21. PubMed ID: 8555081
[TBL] [Abstract][Full Text] [Related]
13. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
Dimitrov JD; Roumenina LT; Plantier JL; Andre S; Saboulard D; Meslier Y; Planchais C; Jacquemin M; Saint-Remy JM; Atanasov BP; Kaveri SV; Lacroix-Desmazes S
J Thromb Haemost; 2010 Jul; 8(7):1524-31. PubMed ID: 20374449
[TBL] [Abstract][Full Text] [Related]
14. Role of factor VIII C2 domain in factor VIII binding to factor Xa.
Nogami K; Shima M; Hosokawa K; Suzuki T; Koide T; Saenko EL; Scandella D; Shibata M; Kamisue S; Tanaka I; Yoshioka A
J Biol Chem; 1999 Oct; 274(43):31000-7. PubMed ID: 10521497
[TBL] [Abstract][Full Text] [Related]
15. An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor.
Foster PA; Fulcher CA; Houghten RA; Zimmerman TS
J Biol Chem; 1988 Apr; 263(11):5230-4. PubMed ID: 2895765
[TBL] [Abstract][Full Text] [Related]
16. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
Kroner PA; Foster PA; Fahs SA; Montgomery RR
Blood; 1996 Feb; 87(3):1013-21. PubMed ID: 8562925
[TBL] [Abstract][Full Text] [Related]
17. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site.
Pratt KP; Qian J; Ellaban E; Okita DK; Diethelm-Okita BM; Conti-Fine B; Scott DW
Thromb Haemost; 2004 Sep; 92(3):522-8. PubMed ID: 15351848
[TBL] [Abstract][Full Text] [Related]
18. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect.
Nogami K; Shima M; Nakai H; Tanaka I; Suzuki H; Morichika S; Shibata M; Saenko EL; Scandella D; Giddings JC; Yoshioka A
Br J Haematol; 1999 Oct; 107(1):196-203. PubMed ID: 10520041
[TBL] [Abstract][Full Text] [Related]
19. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor.
Foster PA; Fulcher CA; Marti T; Titani K; Zimmerman TS
J Biol Chem; 1987 Jun; 262(18):8443-6. PubMed ID: 3110147
[TBL] [Abstract][Full Text] [Related]
20. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain.
Hamer RJ; Koedam JA; Beeser-Visser NH; Bertina RM; Van Mourik JA; Sixma JJ
Eur J Biochem; 1987 Jul; 166(1):37-43. PubMed ID: 3109914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
